Variant calling significantly impacts cancer treatment by enabling precision medicine. By identifying actionable mutations, clinicians can tailor therapies to the individual genetic profile of a patient's cancer. For example, the presence of an EGFR mutation in non-small cell lung cancer can make a patient eligible for targeted therapies like gefitinib or erlotinib.
